ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The clinical study was approved by the local ethics committee (protocol of the meeting of the ethics committee at the Lopukhin Federal Research and Clinical Center of Physical–Chemical Medicine of Federal Medical Biological Agency no. 2022/10/05 dated October 5, 2022) and was performed by taking blood samples from patients with T2DM (n = 12) and healthy volunteers (n = 6). Each participant in the study provided a voluntary written informed consent after receiving an explanation of the potential risks and benefits, as well as the nature of the upcoming study.

CONFLICT OF INTEREST

The authors of this work declare that they have no conflicts of interest.